JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 02, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 4, 2017 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2017 financial results and a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 17334187.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858.717.2310 Email: [email protected]
